

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

北 斗 嘉 藥 業 股 份 有 限 公 司
BAYTACARE PHARMACEUTICAL CO., LTD.*
(a joint stock limited company incorporated in the People's Republic of China)
(Stock Code: 8197)

RESUMPTION GUIDANCE

Reference is made to the announcement (the “**Announcement**”) of Baytacare Pharmaceutical Co., Ltd.* (the “**Company**”) dated 26 September 2018 in relation to, among others, the listing status of the Company. Terms defined herein have the same meaning as defined in the Announcement, unless otherwise defined.

The Company received a letter from the Stock Exchange dated 4 October 2018, in which the Stock Exchange sets out the following resumption guidance (“**Resumption Guidance**”) for the Company:

- Demonstrate its compliance with Rule 17.26 of the GEM Listing Rules.

The Stock Exchange further indicated that it may modify or supplement the Resumption Guidance if the Company’s situation changes.

Under the Rule 9.14A(1) of the GEM Listing Rules, the Stock Exchange may cancel the Company’s listing if trading in its shares has been suspended for 12 continuous months from the date of trading suspension. The 12-month period will expire on 26 September 2019. If the Company fails to remedy the issues causing its trading suspension and fully comply with the GEM Listing Rules to the Stock Exchange’s satisfaction and resume trading in its shares by 26 September 2019, the Listing Department will recommend the GEM Listing Committee to proceed with the cancellation of the Company’s listing. In addition, the Stock Exchange has the right to impose a shorter specific remedial period, where appropriate.

The Company is taking appropriate steps to remedy the issues causing its trading suspension and will use its best endeavours to resume trading in its shares as soon as practicable. The Company will keep its shareholders and potential investors informed of the progress as and when appropriate.

Continued Suspension of trading

Trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on 27 September 2018 and will remain suspended until further notice.

By Order of the Board
Baytacare Pharmaceutical Co., Ltd.*
Cui Bingyan
Executive Director

Beijing, People's Republic of China, 10 October 2018

As at the date of this announcement, the executive Directors are Cui Bingyan, Fang Yao and Guo Aiqun; the non-executive Directors are Shi Peng and Cao Yang; and the independent non-executive Directors are Hui Lai Yam, Gao Zhikai and Chen Youfang.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Company Announcements" page of the website of GEM at www.hkgem.com for at least 7 days from the date of the publication and the Company's website at www.baytacare.com from the date of this announcement.

* *for identification purposes only*